COVID-19 Updates

Date: April 18, 2022 Issue #:  1648Summary:  The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer-BioNTech(Comirnaty) and Moderna(Spikevax) to allow for their use as a second booster dose ≥4 months after a first booster dose in adults ≥50 years old and in persons aged ≥12 years (Pfizer) or ≥18 years (Moderna) who have undergone solid organ transplantation or have a condition that compromises the immune system to a similar extent.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: bebtelovimab Comirnaty COVID-19 Lagevrio molnupiravir nirmatrelvir Paxlovid remdesivir Ritonavir sotrovimab Spikevax vaccines Veklury Source Type: research